KRAS and non-small cell lung carcinoma: The aberrant activation of KRAS signaling is a common driver of tumor development and progression in different types of cancers, including pancreatic cancer (59), non-small-cell lung cancer (60–63), colorectal cancer and melanoma (64), and pancreatic cancer (65).